Superworth

Indivior Pharmaceuticals INDV

Drug Manufacturers - General, Healthcare
$36.28
+2.57%
Market cap
$4.3B
PE
10.2×
1y median 19.9×
Forward PE
n/m
not a meaningful number
Price to sales
3.1×
EV/EBIT
8.2×
Revenue, 12 months
$1.4B
+16% on a year ago
Net margin
32.8%
Free cash flow yield
0.7%

Indivior Pharmaceuticals trades at 10.2× trailing earnings, cheaper than 98% of the last ten years. Revenue was $1.4B over the last twelve months, up 16% on a year earlier with a 33% net margin.

Charts

Financials

Income statement for INDV, by quarter
Income statementQ1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$284M$299M$307M$299M$266M−6%$302M+1%$314M+2%$358M+20%$317M+19%$343M+14%$356M+13%
Cost of revenue$38M$79M$66M$48M$44M+16%$52M−34%$83M+26%$67M+40%$40M−9%$50M−4%$51M−39%
Gross profit$246M$220M$241M$250M$221M−10%$250M+14%$230M−5%$292M+17%$277M+25%$294M+18%$305M+33%
R&D$28M$26M$22M$31M$22M−21%$21M−19%$33M+50%$21M−32%$16M−27%$12M−43%$5M−85%
SG&A$143M$152M$142M$175M$133M−7%$158M+4%$154M+9%$189M+8%$124M−7%$122M−23%$119M−23%
$75M−$118M$35M$46M$66M−12%$72M$43M+23%$81M+76%$137M+108%$160M+122%$180M+319%
Interest expense$9M$9M$11M$13M$12M+33%$15M+67%$12M+9%$6M−54%$7M−42%$2M−87%$2M−83%
Pre-tax income$73M−$121M$30M$38M$59M−19%$62M$37M+23%$81M+113%$115M+95%$160M+158%$182M+392%
$11M−$23M$8M$17M$11M+0%$44M−$5M−$21M$26M+136%$38M−14%$45M
Net income$61M−$97M$22M$21M$47M−23%$18M$42M+91%$102M+386%$89M+89%$122M+578%$137M+226%
$0.45−$0.72$0.16$0.17$0.38−16%$0.14$0.33+106%$0.78+359%$0.69+82%$0.98+600%$1.12+239%
137M135M133M127M125M−9%126M−7%129M−3%131M+3%129M+3%124M−2%122M−5%

EPS, diluted: Q4 FY24 and Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Indivior Pharmaceuticals' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
INDVIndivior Pharmaceuticals$4.3B10.2×19.9×3.1×+16%32.8%
ARQTArcutis Biotherapeutics$3.9B142×117×8.5×+76%6.1%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
OGNOrganon$3.6B18.2×6.0×0.6×−3%3.5%
LGNDLigand Pharmaceuticals$6.1B32.7×37.6×21.1×+55%67.9%
AMRXAmneal Pharmaceuticals$6.5B41.7×51.4×2.1×+9%5.0%
NRIXNurix Therapeutics$2.8B11.1×11.0×4.0×n/m42.0%
KNSAKiniksa Pharmaceuticals International$7.1B93.6×87.6×8.4×+59%9.6%
ALKSAlkermes plc.$7.5B118×16.0×4.5×+11%4.0%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
Peer median$3.8B31.4×26.8×4.3×+18%12.6%

More on Indivior Pharmaceuticals

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .